Summary The association between Ki-ras mutations and proliferation activity was investigated in a comprehensive series of biliary tract carcinomas (BTCs). We precisely microdissected samples of tissue from paraffin-embedded sections of 77 BTCs including 22 intrahepatic cholangiocarcinomas (ICCs), 36 extrahepatic cholangiocarcinomas (ECCs), and 19 gall bladder carcinomas (GBCs). Ki-ras mutations at exons 1 and 2 were determined by the polymerase chain reaction -single strand conformation polymorphism (PCR-SSCP) method and confirmed by direct sequencing. Proliferation activity was immunohistochemically assessed to generate proliferating cell nuclear antigen labelling indices (PCNA LIs). Ki-ras mutations were detected in 10 of 22 ICCs (45%), 24 of 36 ECCs (67%), and in 16 of 19 GBCs (84%). The frequency of Ki-ras mutations in peripheral type ICCs was 33% (4 of 12) and that in the hilar type ICCs was 60% (6 of 10). In ECCs the highest value of 82% (9 of 11) was found for carcinomas located in the lower part of the biliary tree. Mean PCNA LI in mutation-positive BTCs was significantly elevated compared with the mutation-negative value. These results indicate frequent involvement of Ki-ras mutations in BTCs, especially in GBCs and in distal ECCs, and that carcinomas harbouring a mutation feature high cell proliferation activity.
In the last decade, the significance of alterations of oncogenes or tumour-suppressor genes has become a paradigm in cancer research. It is now generally accepted that accumulation of damage to critical regulatory genes in a multistep manner is the essential mechanism of human tumour pathogenesis (Marx, 1989; Fearon et al., 1990) . Recent investigations of suppressor gene transfection or blocking the function of mutated oncogenes have provided strong support for this conclusion and offer clues to new anti-cancer treatment approaches (Krzyzoiak et al., 1992; Sumi et al., 1992; Shirasawa et al., 1993; Fujiwara et al., 1994) . For example, abrogating the mutated-ras-mediated pathway which exerts transforming activity has been reported to be effective for growth inhibition, at least in in vitro models.
Biliary tract carcinomas (BTCs) are characterised by a poor prognosis, because of difficulties in early detection and radical surgical removal as well as being refractory to chemoand radiotherapy (Boerma, 1990; Ohashi et al., 1994a) . Basic information on gene alterations is therefore required to understand the mechanisms of their pathogenesis and to facilitate development of genetic approaches to therapy. In terms of gene target therapy, mutated-ras has been considered as a candidate from several reports of experimental therapy, describing disruption of the Ki-ras gene or depletion of farnesyl isoprenoid to inhibit mutated-rasmediated cell growth (Krzyzoiak et al., 1992; Sumi et al., 1992; Shirasawa et al., 1993) . Thus, an accurate estimation of the frequency of association between Ki-ras gene mutations and BTCs is important.
The reported frequencies of Ki-ras mutations in BTC have varied greatly (Almoguera et al., 1988; Tada et al., 1990; Capella et al., 1991; Levi et al., 1991; Motojima et al., 1991; Stork et al., 1991; Tsuda et al., 1993; Imai et al., 1994) and the discrepancies require explanation. In most cases, whole materials from sectioned formalin-fixed paraffin-embedded specimens of fresh frozen tissues were used for DNA extraction. The possibility of contamination with quantities of DNA from the interstitial tissue which is prominent in BTCs must be taken into account. We previously reported consistently high frequencies of Ki-ras gene mutations in both intrahepatic cholangiocarcinomas (ICCs) and extrahepatic cholangiocarcinomas (ECCs) using DNA samples extracted from microdissected tissues under the light microscope (Ohashi et al., 1994b) . This approach allows the nature of the sampled cell population to be assessed more accurately.
In the present investigation, we extended our previous studies and estimated the mutation rates of a large series of accumulated BTC cases including gall bladder carcinomas (GBCs). In addition, the study included an evaluation of the possible correlation between Ki-ras mutation and proliferation activity of tumour cells as determined by proliferating cell nuclear antigen (PCNA) staining, since an understanding of proliferation activity of the tumour cells is very important to provide evidence of biological malignancy (Kitamoto et al., 1993; Ohashi et al., 1994a) . PCNA, a nuclear auxiliary protein for DNA polymerase-6 which is closely linked to the cell cycle, is now generally recognised as a useful marker for detecting proliferating cells (Bravo et al., 1987 (1977) , a peripheral ICC (n = 12) is defined as a tumour originating from the bile duct peripheral to the second fork and a hilar ICC (n = 10) is one originating from the bile duct between the second fork and the hepatic hilus. Proximal (n = 17), middle (n = 8) and distal (n = 11) ECCs are defined as tumours originating from the bile duct between the hepatic hilus and the cystic duct junction, the cystic duct junction and the upper margin of the pancreas, and the upper margin of the pancreas and the ampullar region respectively. To eliminate bias in interpretation of gene alterations, the divisions of ICCs and ECCs were performed by surgeons and pathologists without knowledge of the results of the gene alterations by unanimous consent.
DNA extraction and amplification A microdissection method was used for tissue harvesting as previously described (Tsutsumi et al., 1993b; Yanagisawa et al., 1993; Ohashi et al., 1994) . Briefly, serial sections 4-and 20-im thick were cut and attached to slide glasses. The 4 ,um sections were stained with haematoxylin and eosin (H&E) to confirm the presence of carcinoma tissues. The 20-am sections were stained with haematoxylin after deparaffinisation. With comparative microscopic observation of the H&E stained section for orientation, tumour cells were cut out using 23-G syringe needles, excluding mesenchymal cells as far as possible. As a countermeasure against heterogeneity within single tumours, ten parts in each case were arbitrarily selected from peripheral and central regions and approximately 1000 cells per case were harvested. These samples were cleaned with ethanol, completely dried and incubated in 400 ml of lysis buffer [10 mM Tris-HCl (pH 8.3), 50 mM potassium chloride, 2.5 mM magnesium chloride, 0.45% Tween 20) containing proteinase K (0.5 mg ml-1) for 48 h at 55°C following the protocol described by Wright and Manos (1990) . A 159-bp fragment of the first exon of the Kiras gene was amplified by polymerase chain reaction (PCR) using the primers: GGAATTCGACTGAATATAAACTTG a \ cP IC Ki-ras mutations in biliary tract carcinomas K Ohashi et al 9 931 TGG and GGAATTCCTGCACCAGTAATATGC. To target codon 61 of Ki-ras, which belongs to exon 2, the following primers yielding a 116 base pair were used: GGAATTCCTACAGGAAGCAAGTAG and GGAATTC-CTCATGTACTGGTCCCT. After denaturation for 3 min at 95°C 500 ng DNAs or distilled water without DNA as an internal control were allowed to run for 60 s at 92°C, 120 s at 55°C and 120 s at 72°C for 40 cycles.
SSCP and sequencing analysis The PCR products of 159 and 116 bp were analysed by single strand conformation polymorphism (SSCP). Five per cent polyacrylamide gels containing 45 mM Tris-borate (pH 8.3), 4 mM EDTA, and 10% glycerol were prepared, and gel electrophoresis performed at 30W for about 4 h both at 5°C and 30°C constant (LKB Macrophore DNA electrophoresis system, Pharmacia Co, Ltd., Sweden). Gels were dried and exposed to radiographic film at -80°C for about 2 days.
To determine nucleotide sequence alterations detected by mobility shifts in PCR-SSCP analysis, we sequenced the DNAs after their amplification by asymmetric PCR (Gyllensten et al., 1988) . DNA fragments showing a mobility shift compared with the normal control by PCR-SSCP analysis were separated and eluted from the polyacrylamide gel according to the method of Suzuki et al. (1991) . After subsequent PCR using the same primers as described above, amplification reaction mixtures were purified with a Microcon (Amicon, Denvers, MA, USA). For determination of nucleotide sequences, the dideoxy chain-termination method (Sanger et al., 1992) was performed using a dsDNA Case no. , 3, 4, 6, 7, 9, 11, 13, 15, 18, 19, 21 and 22 (arrowheads Figure 2 Schematic illustration of tumour location and the frequencies of Ki-ras mutations in biliary tract carcinomas. Note the high frequencies of mutation in GBC and the lower part (middle and distal) ECCs in the series of BTC. Significant differences in frequencies were found between peripheral ICCs and distal ECCs, peripheral ICCs and GBCs, and proximal ECCs and GBCs. without statistical significance. When the three carcinomas were combined, the mean PCNA LI in Ki-ras mutationpositive cases was significantly elevated compared with mutation-negative cases (P < 0.05).
Discussion
The present observations with a large series of tumours clearly demonstrated frequent involvement of Ki-ras mutations in BTCs, especially in gall bladder and lower bile duct cases. Furthermore, the mutation-harbouring cases demonstrated a significantly higher proliferation activity of the tumour cells than the mutation-negative cases.
It is well recognised that ras gene activation, mostly induced by point mutation, is strongly associated with carcinogenesis. In BTCs, the frequencies reported so far have varied greatly, ranging from 0 to 58% in ICCs (Tada et al., 1990; Tsuda et al., 1993) , 8 to 100% in ECCs (Capella et al., 1991; Levi et al., 1991; Motojima et al., 1991; Stork et al., 1991; Imai et al., 1994) and 0 to 39% in GBCs (Almoguera et Capella et al., 1991; Tada et al., 1990; Imai et al., 1994) . The discrepancies in mutation rates might be accounted for by the different methodologies applied for DNA extraction as well as the small numbers of patients examined in each report. Since BTCs are often rich in interstitial tissues, it is conceivable that contamination with non-tumour cell DNA might mask mutations of tumour cells, resulting in low frequencies of positives when fresh frozen tissue or whole tissues of paraffin-embedded material are used. It has been reported that at least 5-10% cancer cells are needed for detection of gene mutations before amplification for PCR (Burmer et al., 1989) . In this context, the microdissection method is important since we can ensure more than 10% cancer cells even for such interstitial-rich tumours as BTCs. Our previous study showed microdissection and PCR-SSCP analysis to be a reliable method (Ohashi et al., 1994b) and the results were confirmed in the present investigation of a larger series of accumulated cases.
One of the interesting findings in the present study is that the mutation rates differed significantly with the tumour location. The mutation rates were higher in GBCs and distal ECCs compared with other BTCs. Hepatic metabolism of carcinogens leads to the production of mutagenic intermediates which are excreted into bile in the biliary ductules and are collected and concentrated as they pass progressively into intrahepatic and extrahepatic ducts and finally the gall bladder, where one would expect to find the highest concentration of mutagens. These agents are also known to exert a promoting action for cholangiocarcinogenesis (Makino et al., 1985) . Therefore, it is reasonable to speculate that one of the major contributory factors for the differences in mutation rates could be the differences in the concentration of excreted mutagenic intermediates and/or differences in their composition at different sites within the biliary tree.
Ki-ras mutations in biliary tract carcinomas
Nitrosamines such as N-nitrosobis(2-hydropropyl)amine or N-nitrosobis(2-oxopropyl)amine are known to induce not only pancreatic carcinomas but also bile duct carcinomas which harboured mutations in the Ki-ras gene in animal models (Tsutsumi et al., 1993a and b) . These agents produce primarily methyl adducts at the N7 and o6 position of guanine (Lawson et al., 1981; Kokkinakis et al., 1989) . The guanine in the second position of Ki-ras codon 12 (GGT) may be sensitive to mutation owing to flanking nucleotide residues, thus GGT to GAT or to GTT alterations occur (Cerny et al., 1992; Tsutsumi et al., 1993) as also found in the present study. Moreover, differences in susceptibility of different organs to such DNA alterations by these chemicals may play a causative role (Tsutsumi et al., 1993a) . We previously reported a higher frequency of Ki-ras mutations in pancreatic carcinomas than in cholangiocarcinomas induced by the same carcinogen using the hamster animal model. Thus, another hypothetical interpretation is that susceptibility to DNA damage of epithelial cells varies in accordance with the location in the biliary tree.
As a further possible factor influencing mutations in BTC, especially of significance for GBC, anomalous arrangement of the pancreaticobiliary ductal system (APB), which permits reflux of pancreatic juice into the biliary system has been recognised (Komi et al., 1989) . The interaction of pancreatic juice with bile has been reported to play a key role in cholangiocarcinogenesis (Qian et al., 1993) . Ohta et al. (1993) reported that biliary papillomatosis occurring in the bile duct with APB features Ki-ras mutations. APB was a feature of two of the ECC cases in the present study, and these two cases both demonstrated Ki-ras mutations. From these findings, it is reasonable to assume that involvement of Ki-ras mutations during cholangiocarcinogenesis might, in part, be affected by the degree of pancreatic fluid reflux and its concomitant interaction with bile, thus resulting in a very high frequencies of mutation in both distal ECC and GBC.
The narrow spectrum of mutation (GGT to GAT or GTT) in BTCs is noteworthy compared with other types of malignancies such as pancreatic or colon cancer (Forrester et al., 1987; Mariyama et al., 1989; Scarpa et al., 1994) . The method used in the present study for detecting mutation is well established and is generally considered reliable for detecting mutations (Orita et al., 1989) , so a technical basis for the findings seems unlikely. From the aforementioned chemical carcinogen-associated possible carcinogenesis, the narrow spectrum of mutations might well reflect the special characteristics of cholangiocarcinogenesis in Japan. With regard to the genesis without associated Ki-ras mutation, we and another Japanese group previously reported that chronic mechanical irritation by gall stones, parasites or virus infection are possible causal factors from investigation of ICC cases (Tsuda et al., 1993; Ohashi et al., 1995) . However, a separate pathogenesis might be involved with ECC or GBC, and more detailed studies including investigations in animal models are necessary to elucidate this point. This is the first assessment, to the best our knowledge, of the proliferation activity of BTCs in relation to Ki-ras mutations. The present results indicate significantly higher proliferation in mutation-positive cases than in mutationnegative ones. This may suggest a greater propensity of Ki- ras-mutated cases to progress to biological malignancy. Mutations in the ras gene induce drastic increase in the active form of ras protein, in the GTP-bound state, which locks signal transduction in the 'on' position and possibly leads cells into DNA synthesis (Trahey et al., 1987) . From this point of view, harbouring a Ki-ras mutation must represent an advantage in terms of growth and progression.
Finally, the success of mutated Ki-ras-targeted experimental therapy is noteworthy in consideration of contriving therapeutic strategies for BTC in the future (Krzyzoiak et al., 1992; Sumi et al., 1992; Shirasawa et al., 1993) . Considerable anti-proliferative or anti-cancer effects have been exhibited on cultured cell lines and refinement of this approach should
